Proactive Investors - Run By Investors For Investors

CytoDyn to begin proof-of-concept studies for leronlimab to treat liver damage caused by NASH

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors that the Cleveland Clinic will evaluate if its flagship drug leronlimab can prevent Non-Alcoholic Steatohepatitis (NASH), or "fatty liver" in mice.

Pourhassan says the Vancouver, Washington-based company will begin proof-of-concept studies of leronlimab in NASH in an 'expedited' fashion.

 
View full CYDY profile View Profile

CytoDyn Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use